Applicant: Kunihiro Hattori et al. Attorney's Docket No.: 14875-0161US1 / C1-A0313P2-US

Serial No.: 10/575,905
Filed: April 30, 2007
Page: 2 of 10

## Amendments to the Specification:

Please replace the title with the following amended title:

DOUBLE SPECIFIC BISPECIFIC ANTIBODIES SUBSTITUTING FOR

## FUNCTIONAL PROTEINS

Please replace the paragraph beginning at page 9, line 16, with the following amended paragraph:

[35] The composition according to [31], wherein the disorder that arises and/or progresses as a result of an activity decrease of blood coagulation factor VIII and/or activated blood coagulation factor VIII is von Willebrand's Willebrand's disease.

Please replace the paragraph beginning at page 28, line 3, with the following amended paragraph:

Although the dosage of the pharmaceutical compositions of the present invention is appropriately determined considering the type of formulation, method of administration, age and body weight of patients, symptoms of patients, type and progress of disease, etc, and ultimately by doctors, generally, doses of 0.1-2000 mg/day can be divided into one to several oral administrations for adults. The dosage is preferably 1 to 1000 mg/day, more preferably [[5]] 50 to 500 mg/day, and most preferably 100 to 300 mg/day. Although the dosage varies according to the body weight and age of patients, administration methods and such, one skilled in the art can suitably select an appropriate dosage. Preferably, the dosing period is also appropriately determined according to, for example, the healing process of patients.